Latest Targeted therapy Stories
Molecularly-Guided Therapies of Critical Importance for Rare Cancers with Fewer Treatment Options IRVING, Texas, Jan.
Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan.
Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan.
Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan.
To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc.
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.
MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions